Research & Development

Research & DevelopmentCurrent Status of Clinical Trials
Type Cell type Product Indication predecessor award Phase I clinical trial Phase II clinical trial Clinical III Award Applied technology

Autologous Immunocytes CBT101* solid cancer (Recurrent Glioblastoma )
 NK-FF
Allogenic Immunocytes Allo-NK solid cancer
 NK-AFF
Neuropathic cells FMD-NPC Parkinson’s Disease (PD)
 EP-NPC
Stem cell CordSTEM-DD Disk Degeneration
 MSC-CORD
CordSTEM-ST Stroke
CordSTEM-AS Asherman's syndrome
CordSTEM-ARDS Severe respiratory disease
ES-MSC premature ovarian failure
 H-ES
hESC-RPE Macular Degeneration (AMD)
 Astellas(US)Partnership
hESC-RPE Stargard's disease

*U.S. FDA designates rare drug for recurrent malignant neuropods (2020.9)
CHA Biotech program Partnered program


 
CEO Message
Vision
History
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Business
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
IR Presentations